Sarah Mayfield, MD
Pediatrics · Bowling Green, KYNPI 1992732820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 28.1% of the total. Reporting peaked in 2023 at $1,210 and has fallen 80.5% since, to $236 in 2024. Among pediatrics clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$597
- GSK$544
- Lilly USA, LLC$525
- Pfizer$278
- AstraZeneca$211
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,826100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $1,360 |
| Novo Nordisk | 57 | $597 |
| GSK | 32 | $544 |
| Lilly USA, LLC | 36 | $525 |
| Pfizer | 23 | $278 |
| AstraZeneca | 14 | $211 |
| Corium, LLC | 6 | $192 |
| Supernus Pharmaceuticals, Inc. | 11 | $171 |
| Ironshore Pharmaceuticals Inc. | 9 | $143 |
| Sanofi Pasteur Inc. | 8 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $93 |
| Cranial Technologies, Inc | 5 | $71 |
| Merck | 5 | $62 |
| Mannkind Corporation | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Seqirus USA Inc | 2 | $36 |
| Medtronic(2 entities) | 2 | $32 |
| Siemens Medical Solutions USA, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Amgen | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Sobi, Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Abbott | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,837 in reported general payments places this provider in the 95th percentile of 777 pediatrics providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $59,575 |
| EliquisApixaban | 61 | $52,572 |
| TrulicityDulaglutide | 31 | $33,336 |
| MounjaroTirzepatide | 30 | $33,043 |
| JanuviaSitagliptin Phosphate | 25 | $30,826 |
| JardianceEmpagliflozin | 22 | $27,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $21,044 |
| FarxigaDapagliflozin Propanediol | 33 | $19,831 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,169 |
| Tiotropium Bromide | 12 | $7,933 |
| MyrbetriqMirabegron | 13 | $6,531 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,149 |
| Duloxetine Hcl | 106 | $3,274 |
| Levothyroxine Sodium | 222 | $2,537 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $525 | $66,38061 claims |
| Novo NordiskOzempic | $597 | $59,57556 claims |
| PfizerEliquis | $278 | $52,57261 claims |
| MerckJanuvia | $62 | $30,82625 claims |
| Boehringer IngelheimJardiance | $20 | $27,01222 claims |
| AstraZenecaFarxiga, Symbicort | $211 | $23,97952 claims |
| GSKTrelegy Ellipta | $544 | $21,04420 claims |
| AbbVieSynthroid, Armour Thyroid | $1,360 | $2,27343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 777 pediatrics providers in Kentucky.
Other pediatrics in Bowling Green
- Paul KnieryBowling Green$4K
- Zahid FraserBowling Green$3K
- Jeffrey BitterlingBowling Green$3K
- Pippa Pinckley-StewartBowling Green$3K
- John SmithBowling Green$3K
- Sirish PalleHyden$89K
- Christian BerkhahnLouisville$85K
- Maurice AllgeierLouisville$38K
- Stanley BlockBardstown$34K
- Michael SimonNicholasville$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.